Patient trial also has potential to improve understanding around which patients with knee osteoarthritis are most likely to benefit from novel hydrogel
A new study to confirm the clinical effectiveness of a novel treatment for knee osteoarthritis in a UK setting is underway at The Robert Jones and Agnes Hunt Orthopaedic Hospital NHS Foundation Trust (RJAH).
Funded by non-biodegradable hydrogel pioneers, Contura Orthopaedics, with a research grant of over £150,000, this first study of its kind in the UK aims to determine the pathways on which Contura’s minimally invasive treatment, the 2.5 iPAAG (intra-articular polyacrylamide hydrogel injection) single injection Arthrosamid® [based on 97.5% water and 2.5% cross-linked polyacrylamide] acts when used to treat patients with knee osteoarthritis (OA) by detecting the changes which occur in the joint after the injection is administered.
In the UK, approximately 4.11 million people are affected by knee OA, which causes discomfort, chronic pain and mobility issues. The economic burden of the conditio